Marker Therapeutics is a clinical-stage immuno-oncology company focusing on the development and commercialization of T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Co. is developing two pipelines of product candidates as part of its MultiTAA-specific T cell program: the autologous T cells for the treatment of lymphoma, multiple myeloma, and selected solid tumors and the allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. Co. is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors. The MRKR stock yearly return is shown above.
The yearly return on the MRKR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MRKR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|